EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer

Minhong Huang, Sisi Qin, Huanyao Gao iD, Wootae Kim iD, Fang Xie, Ping Yin, August John iD, Richard M Weinshilboum, Liewei Wang

Cells · 2024

DOI: 10.3390/cells13191622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Minhong Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense, Mayo Clinic Centre for Individualized Medicine, A. T. Suharya and Ghan 663 D. H.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most patients with metastatic prostate cancer eventually develop resistance to primary androgen deprivation therapy. To identify predictive biomarker for Abiraterone acetate/prednisone resistance, we screened alternative splice variants between responders and non-responders from the PROMOTE clinical study and pinned down the most significant variant, CENPK–delta8. Through preclinical patient-derived mouse xenograft (PDX) and 3D organoids obtained from responders and non-responders, as well as in vitro models, aberrant CENPK–delta8 expression was determined to link to drug resistance via enhanced migration and proliferation. The FLNA and FLOT1 were observed to specifically bind to CENK–delta8 rather than wild-type CENPK, underscoring the role of CENPK–delta8 in cytoskeleton organization and cell migration. Our study, leveraging data from the PROMOTE study, TCGA, and TCGA SpliceReq databases, highlights the important function of alternative splice variants in drug response and their potential to be prognostic biomarkers for improving individual therapeutic outcomes in precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansAnimalsMiceAlternative SplicingDrug Resistance, NeoplasmNeoplasm MetastasisCell ProliferationCell Line, TumorAndrostenesCell MovementProtein IsoformsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

3D organoiddrug resistancemetastatic castration-resistant prostate cancerpatient-derived xenograftsplice variant

Substanzen

abirateroneAndrostenesProtein Isoforms

Autor:innen und Institutionen

  • Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
  • Department of Integrated Biomedical Science, Soonchunhyang Institute of Medi-Bio Science (SIMS), Soonchunhyang University, Cheonan 31151, Chungcheongnam-do, Republic of Korea.
  • Division of Medical Oncology and Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

ORCID-Profile: Huanyao Gao, Wootae Kim, August John

Förderung

  • United States Department of Defense
  • Mayo Clinic Centre for Individualized Medicine
  • A. T. Suharya and Ghan 663 D. H
  • Gail and Joseph Gassner
  • Mayo Clinic Schulze Cancer for Novel Therapeutics in Cancer Re-664 search
  • Department of Defense

Zitieren

APA

Huang, M., Qin, S., Gao, H., Kim, W., Xie, F., Yin, P., John, A., Weinshilboum, R. M., & Wang, L. (2024). The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Cells. https://doi.org/10.3390/cells13191622

Vancouver

Huang M, Qin S, Gao H, Kim W, Xie F, Yin P, et al. The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Cells. 2024. doi:10.3390/cells13191622

BibTeX
@article{Huang2024,
  author = {Huang, Minhong and Qin, Sisi and Gao, Huanyao and Kim, Wootae and Xie, Fang and Yin, Ping and John, August and Weinshilboum, Richard M and Wang, Liewei},
  title = {The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13191622}
}
Kostenlos starten →